IL18 and Cirrhosis: In a study involving 112 patients with cirrhosis with either prerenal AKI, HRS, or ATI, Belcher et al. evaluated uNGAL, IL-18, KIM-1, and L-FABP, concluding that each biomarker effectively distinguished ATI from non-tubular causes of renal damage, with NGAL exhibiting superior performance.